Mesoblast (ASX:MSB) completed a global private placement to existing US, UK, and Australian shareholders, raising AU$260 million at AU$2.50 per share, according to a Tuesday filing with the Australian bourse.
The proceeds will fund the US commercial launch of Ryoncil for pediatric steroid-refractory acute graft-versus-host disease, accelerate the second phase three study in inflammatory chronic low back pain, expand commercial manufacturing activities, and fund working capital and general corporate purposes, the filing said.
The company's shares fell almost 7% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.